Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron for weight loss in adults with obesity or overweight and weight-related comorbidities (without type 2 diabetes)
jRCT2051250032Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of orforglipron in obesity and Overweight (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight. Started Jun 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051250032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250032.